EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity

Rui Chen, Ziqin Kang, Wenhao Li, Tianshu Xu, Yongqiang Wang, Qiming Jiang, Yuepeng Wang, Zixian Huang, Xiaoding Xu, Zhiquan Huang iD

Journal of Extracellular Vesicles · 2024

DOI: 10.1002/jev2.12490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2024. Verfasst von Rui Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China. Hauptthemen laut MEDLINE: Extracellular Vesicles, B7-H1 Antigen, CD3 Complex, T-Lymphocytes. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sun Yat-sen Pilot Scientific Research Fund, National Natural Science Foundation of China, Guangdong Provincial Medical Science and Technology Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular vesicles (EVs) are emerging as promising carriers for the delivery of therapeutic biologics. Genetic engineering represents a robust strategy for loading proteins of interest into EVs. Identification of EV‐enriched proteins facilitates protein cargo loading efficiency. Many EV‐enriched proteins are sorted into EVs via an endosomal sorting complex required for transport (ESCRT)‐dependent pathway. In parallel, viruses hijack this EV biosynthesis machinery via conserved late domain motifs to promote egress from host cells. Inspired by the similarity of biogenesis between EVs and viruses, we developed a synthetic, Late domain‐based EV scaffold protein that enables the display of a set of single chain variable fragments (scFvs) on the EV surface. We named this scaffold the Late domain‐based exosomal antibody surface display platform (LEAP). We applied the LEAP scaffold to reprogramme HEK293T cell‐derived EVs to elicit T‐cell anti‐tumor immunity by simultaneously displaying αPD‐L1 and αCD3 scFvs on the EV surface (denoted as αPD‐L1×αCD3 bispecific T‐cell engaging exosomes, BiTExos). We demonstrated that αPD‐L1×αCD3 BiTExos actively redirected T cells to bind to PD‐L1 + tumor cells, promoting T‐cell activation, proliferation and tumoricidal cytokine production. Furthermore, the αPD‐L1×αCD3 BiTExos promoted T‐cell infiltration into the tumor microenvironment to mitigate the tumor burden in vivo. Our study suggested that the LEAP scaffold may serve as a platform for EV surface display and could be applied for a broad range of EV‐based biomedical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesB7-H1 AntigenCD3 ComplexT-LymphocytesSingle-Chain AntibodiesHumansAnimalsHEK293 CellsMiceExosomesNeoplasmsLymphocyte Activation

Stichwörter der Autor:innen

EV engineeringbispecific T‐cell engagerimmunotherapylate domain

Substanzen

B7-H1 AntigenCD3 ComplexSingle-Chain AntibodiesCD274 protein, human

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.
  • Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.

ORCID-Profile: Zhiquan Huang

Förderung

  • Sun Yat-sen Pilot Scientific Research Fund
  • National Natural Science Foundation of China
  • Guangdong Provincial Medical Science and Technology Research
  • The Guangzhou Science and Technology Project
  • The Science and Technology Program of Guangdong
  • The Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology
  • The Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University

Zitieren

APA

Chen, R., Kang, Z., Li, W., Xu, T., Wang, Y., Jiang, Q., Wang, Y., Huang, Z., Xu, X., & Huang, Z. (2024). Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.12490

Vancouver

Chen R, Kang Z, Li W, Xu T, Wang Y, Jiang Q, et al. Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity. Journal of Extracellular Vesicles. 2024. doi:10.1002/jev2.12490

BibTeX
@article{Chen2024,
  author = {Chen, Rui and Kang, Ziqin and Li, Wenhao and Xu, Tianshu and Wang, Yongqiang and Jiang, Qiming and Wang, Yuepeng and Huang, Zixian and Xu, Xiaoding and Huang, Zhiquan},
  title = {Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity},
  journal = {Journal of Extracellular Vesicles},
  year = {2024},
  doi = {10.1002/jev2.12490}
}
Kostenlos starten →